TAS-117
- Generic Name
- TAS-117
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N4O2
- CAS Number
- 1402602-94-1
- Unique Ingredient Identifier
- QI52W1ZIIB
- Background
TAS-117 is under investigation in clinical trial NCT03017521 (K-BASKET, TAS-117, PI3K/AKT Gene Aberration).
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
Phase 1
Terminated
- Conditions
- Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsAdvanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04770246
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
K-BASKET, TAS-117, PI3K/AKT Gene Aberration
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 13
- Registration Number
- NCT03017521
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath